-+ 0.00%
-+ 0.00%
-+ 0.00%

Jim Cramer Rejects UiPath Despite Cheap Valuation, Backs Affirm

Benzinga·11/20/2026 12:52:38
Listen to the news

On CNBC’s “Mad Money Lightning Round,” Jim Cramer said UiPath Inc. (NYSE:PATH) is a “cheap, cheap stock, but it has no catalyst, so I have to vote it off the island.”

UiPath said it will report third-quarter fiscal 2027 financial results after the closing bell on Thursday, Dec. 3.

Karman Holdings Inc. (NYSE:KRMN) is so “darn cheap. I can’t go against it here. I have to tell you, I think you got something right here,” Cramer said.

On Nov. 5, Karman reported better-than-expected third-quarter financial results and raised its FY26 sales guidance above estimates.

When asked about Affirm Holdings Inc. (NASDAQ:AFRM), he said, “We’re fighting the Fed if we buy the stock. If you want to start up a new position, I bless it right here.”

Affirm, on Nov. 5, reported first-quarter revenue of $1.262 billion, up 35% year-over-year. The revenue total beat a Street consensus estimate of $1.211 billion, according to data from Benzinga Pro. The company reported first-quarter earnings of 47 cents per share, beating a Street consensus estimate of 38 cents per share.

Cramer said Onto Innovation Inc. (NYSE:ONTO) is a good company, but it’s going to move lower because it’s “too expensive in an environment where the Fed is fighting inflation.”

On Nov. 16, Onto Innovation announced a $400 million share repurchase program.

When asked about NIO Inc. (NYSE:NIO), he said, “I got to tell you, $2 stocks, you know where they can go? They stop at zero, and that’s always been the saving grace of a $2 stock. I suggest that you, as long as you don’t mind losing the two bucks, you can hold on for it.”

Nio will report unaudited third-quarter financial results on Tuesday, Dec. 1.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is an “inexpensive” stock, Cramer said. “I happen to like his partner Regeneron (NASDAQ:REGN) more, though. Just for the record, Regeneron, Vertex (NASDAQ:VRTX), and Amgen (NASDAQ:AMGN) all work better.”

On Nov. 4, Alnylam Pharmaceuticals announced it authorized a $1 billion share repurchase program.

Price Action:

  • UiPath shares fell 4.3% to settle at $11.23 on Thursday.
  • Karman shares declined 3.5% to close at $32.99 during the session.
  • Affirm shares dipped 3.4% to settle at $56.91.
  • Onto Innovation shares fell 2.5% to close at $195.93.
  • Nio shares declined 4% to settle at $2.66 on Thursday.
  • Alnylam Pharmaceuticals shares slipped 1.1% to close at $147.82.

Photo: created using images / Shutterstock